TScan Therapeutics Gears Up for Key Health Care Conference
WALTHAM, Mass. – TScan Therapeutics, Inc. (TCRX), a prominent player in the biotechnology sector focused on revolutionary T cell receptor (TCR)-engineered therapies for cancer treatment, has announced an upcoming presentation at a key industry event. This event will take place during the TD Cowen 45th Annual Health Care Conference, set in a prestigious venue in Boston on a Wednesday afternoon.
What to Expect from the Event
The presentation represents a significant opportunity for TScan to highlight its advancements and share insights on its clinical-stage TCR-T therapies aimed at treating cancer effectively. The timing of the presentation is particularly exciting, as these innovative therapies are designed to offer personalized treatment options for patients battling various forms of cancer.
About TScan's Innovative Therapies
TScan Therapeutics is on the cutting edge of biotechnology with its focus on TCR-engineered T cell therapies, which are showing great promise for treating patients with hematologic cancers. The leading therapy candidate, developed under the ALLOHA™ Phase 1 heme trial, is geared toward preventing relapse in patients who have undergone allogeneic hematopoietic cell transplantation.
Personalized Medicine Approach
Additionally, TScan has established its ImmunoBank, a unique repository that houses therapeutic TCRs. This bank contains TCRs that recognize a wide range of targets and align with multiple human leukocyte antigen (HLA) types. This innovative repository allows for the potential creation of customized multiplex TCR-T therapies, enhancing treatment options for patients with solid tumors through the PLEXI-T™ Phase 1 trial.
Webcast Availability
For those unable to attend, TScan will offer a webcast of the presentation, providing viewers around the world the chance to engage with the content. The archived version will be available on TScan's official website for 90 days after the conclusion of the event, ensuring ample opportunity for interested parties to access this valuable information.
Connect with TScan Therapeutics
For further inquiries, TScan Therapeutics invites interested individuals to reach out to their investor relations team. VP Heather Savelle is available for comments, and can be reached directly via phone. She is committed to keeping stakeholders informed about TScan's developments and strategic direction as the company continues to push boundaries in cancer therapy research.
Contacts
Heather Savelle
VP, Investor Relations
857-399-9840
hsavelle@tscan.com
Frequently Asked Questions
What is the focus of TScan Therapeutics?
TScan Therapeutics focuses on developing T cell receptor (TCR)-engineered therapies aimed at treating various types of cancer.
When is TScan's presentation at the conference?
The presentation will take place on a Wednesday afternoon during the TD Cowen 45th Annual Health Care Conference.
How can I view the presentation?
A webcast of the presentation will be available on the company's website for those unable to attend in person.
What are the leading products being developed by TScan?
The leading products include TCR-T therapies for hematologic malignancies and personalized treatments through their ImmunoBank.
Who should I contact for more information about TScan?
You can reach out to Heather Savelle, VP of Investor Relations, for inquiries regarding TScan's initiatives.
